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Abstract
Background: Tuberculosis (TB) patients face numerous difficulties adhering to the long-term, rigorous TB treatment
regimen. Findings on TB patients’ treatment adherence vary across existing literature and official reports. The
present study attempted to determine the actual treatment adherence of new TB patients and to identify factors
leading to non-adherence.
Methods: A prospective cohort of 481 newly confirmed TB patients from three counties in western China were
enrolled during June to December 2012 and was followed until June 2013. Patients who missed at least one dose
of drugs or one follow-up re-examination during the treatment course were deemed as non-adherent. Influencing
factors were identified using a logistic regression model.
Results: A total of 173 (36.0 %) patients experienced non-adherence and the loss to follow-up cases reached
136 (28.2 %). Only 13.9 % of patients took drugs under direct observation, and 60.5 % of patients were supervised
by phone calls. Factor analyses suggested that patients who were observed by family members (OR:5.54, 95 %
CI:2.87–10.69) and paying monthly service expenses above 450 RMB (OR:2.08, 95 % CI:1.35–3.19) were more likely
to be non-adherent, while supervision by home visit (OR:0.06, 95 % CI:0.01–0.28) and phone calls (OR:0.27, 95 %
CI:0.17–0.44) were protective factors.
Conclusions: Despite recent efforts, a large proportion of newly confirmed TB patients could not adhere to
standard TB treatment, and patients’ lost to follow-up was still a serious problem. Poor treatment supervision and
heavy financial burden might be the main causes for non-adherence. More needs to be done to enhance
treatment supervision policies and financial supports to both health providers and TB patients.
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Background
Tuberculosis (TB) remains a major threat to global public
health, with an estimated 9.6 million new cases and 1.5
million deaths worldwide in 2014 [1]. Standard anti-TB
treatment requires patients to take a complex combin-
ation of drugs every other day, lasting for 6 months for
new patients and 8 months for retreatment patients [2].
Such long-term, strict regimens is challenging for TB
patients who may not adhere to their prescribed treatment
due to treatment interruption or drop-out [3]. Non-
adherence is the most common cause of treatment failure
and disease relapse, which can lead to prolonged infection,
transmission, drug resistance and mortality [3, 4]. Directly
observed therapy (DOT), which requires TB patients to
take medicine under the direct observation of health
workers or family members, was the key element of
the DOTS strategy recommended by the World Health
Organization (WHO) and was shown effective in
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improving adherence to anti-TB treatment [5]. However,
DOT coverage rates were still low and made little im-
provement on treatment adherence in some resource-
limited countries [6, 7].
Even with over 300 million USD funding from the
World Bank, Global Found and other international agen-
cies, and with counterpart funding from the Chinese gov-
ernment each year [8, 9], TB control remains poor. China
still reports the world’s second highest TB prevalence. As
WHO reported, 0.8 million Chinese people were esti-
mated to have fallen ill with TB in 2014 and 2 % of those
new TB cases were HIV-positive [1]. According to the fifth
National TB Epidemiological Survey in 2010, the country’s
active TB prevalence had “almost no change” during the
past decade (466/100 000 in 2000 vs. 459/100 000 in
2010) [10]. Non-adherence to TB treatment was consid-
ered an important cause of the gap between high financial
inputs and poor performance in TB control [11].
The national TB survey also reported that 25.3 % of
TB patients missed more than one dose of anti-TB drugs
[10]. Existing studies undertaken in both western and
eastern Chinese provinces also showed the non-adherence
rate to range from 9.4 to 25.9 %. Factors affecting patient
adherence includes education level, adverse effects of treat-
ment, financial status and treatment supervision [12–14].
Most evidence come from retrospective surveys or facility-
based routine reporting records, and findings vary widely
across different sources [12]. We therefore aim to estimate
the current TB treatment adherence in western China and
identify its influencing factors using a prospective cohort
study.
Methods
The study was carried out in Chongqing, China. And
the study followed the STROBE guidelines for a cohort
study.
Chongqing’s TB control and routine strategies to ensure
TB treatment adherence
Chongqing is located in a mountainous area in western
China, with a population of 30 million. Chongqing has
been regarded as “miniature China” because its geographic
feature, urban–rural distribution and socio-economic pro-
file were close to the national [15]. According to China’s
Fifth Tuberculosis Epidemiological Sampling Survey in
2010, the active TB prevalence in Chongqing was 651/100
000 and 70 % of the TB cases were in the rural areas. As
reported by the local infectious diseases information man-
agement system, the notification rate of new and relapse
pulmonary TB cases was 83.3/100 000 and the detection
rate of TB/HIV co-infection was 1.1 % based on patient
screening in 2013. The treatment completion rate of new
and relapse pulmonary TB patients reached 90 %, which
was comparable with the national average [16, 17].
The TB control system in China is a semi-vertical sys-
tem including TB facilities at four levels: national, pro-
vincial, municipal, and county. Chongqing’s TB control
follows the principles of China’s NTP [18]. In each county
of Chongqing, the TB control activities are mainly per-
formed by county TB dispensaries or the hospitals desig-
nated by the local health authorities for TB care (called
“designated hospital” for short), under the supervision of
provincial TB dispensary and Health Bureau. Suspect TB
cases detected in general hospitals/clinics are required to
be referred to TB dispensaries (affiliated with Center for
Disease Control in some counties) or designated hospitals
for treatment and management. According to the NTP
guidelines [18], both new smear-positive and smear-
negative pulmonary TB patients were treated with chemo-
therapy regimen 2H3R3Z3E3/4H3R3 (2-month intensive
phase with Isoniazid, Rifampicin, Pyrazinamide and
Ethambutol every other day, and 4-month continuation
phase with Isoniazid and Rifampicin every other day),
while a new regimen named fixed-dose combination
(FDC, a daily formula combining appropriate doses of
Isoniazid, Rifampicin, Pyrazinamide and Ethambutol) is
recently recommended for TB treatment in Chongqing.
Newly confirmed TB cases should be provided with free
therapy and patients should take each dose of anti-TB
drug under the direct observation by health workers (usu-
ally community or village doctors) during the 6-month
treatment course no matter how far they reside from the
health facility (strict DOT implementation). Some smear-
negative cases are allowed to receive DOT during the first
2-month intensive phase, and then regularly collect TB
drugs at dispensaries/designated hospitals (usually once a
month) during the continuation phase. Health workers
are responsible for reminding the patients about their next
scheduled appointment at the time of medicine collection,
and performing regular home visits for patient manage-
ment. In addition, family members of TB patients are
strongly advised to help patients finish regular treatment;
therefore, both patients and family members should be
educated by health workers on TB and its treatment
(standard regimen, treatment duration, possible adverse
effects, disease evolution, household prevention and con-
sequences of non-adherence).
Sampling and population
The sampling process was performed in three steps: In
step 1, all 39 counties of Chongqing were stratified into
three groups (developed urban area, rural–urban con-
nective area and poor rural area). In step 2, one county
from each group was selected as the study site depend-
ing on our partnership with local health authorities. The
three selected counties were CC (representing urban
counties), SS (representing urban–rural counties) and YY
(representing rural counties). In step 3, all the pulmonary
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TB (PTB) patients newly-diagnosed by chest X-ray
and sputum smear (both positive and negative ones),
registered at the outpatient department of the TB
dispensaries and designated hospitals between 1 June
and 31 December 2012 were enrolled into the cohort.
It is noteworthy that in Chongqing only patients with
severe complications should be hospitalized in the special-
ist TB hospital, and then transferred to local TB dispens-
aries or designated hospitals for subsequent outpatient
treatment and management. Thus, study only recruited
outpatients from the TB dispensaries and designated
hospitals.
Data collection
Patients were recruited to the cohort between June and
December 2012, and were followed for 6 months, as the
recommended treatment course for a new TB case is 6
months. The observation period ended in June 2013.
Data collection was undertaken by a team of trained
researchers at the beginning and end of each month of
the treatment period. Data from both smear-positive
and smear-negative patients were obtained using self-
designed questionnaires, covering information on patient’s
demographic characteristics, type of TB diagnosis, treat-
ment regimen, medication supervision, drug-taking pat-
tern, hospital appointments, adverse effects, treatment
outcomes, costs. In addition to conducting patient survey,
patients’ treatment cards were checked to confirm the
medication collection and hospital visits. Non-adherence
was defined as missing at least one dose of drugs or one
follow-up appointment during the treatment course, in-
cluding interrupters, defaulters and lost to follow-up cases
(detailed definitions see Table 1) [5, 6, 12–14, 19].
Data analysis
Survey data were double entered using EpiData 3.1
software, and analyzed using SPSS 19.0 (Chicago, USA).
Categorical data was described using frequencies and
percentages, while continuous data such as age and in-
come, were converted to categorical variables using the
quartile or median as cutoff points. The associations be-
tween TB adherence and independent variables were
firstly estimated using unconditional logistic regression,
and assessed by odds ratio (OR) with 95 % confidence
intervals (CIs). Then the variables with P-value less than
or close to 0.10 in the univariate analysis were included in
a multivariate logistic regression model (α = 0.05, β = 0.1),
where all independent variables were dummy-coded. Re-
sults were statistically significant if the P-value <0.05. The
model was statistically significant in the model coeffi-
cient test (P < 0.05) and reached a good fit in Hosmer &
Lameshow test (P > 0.20). Significance of the variable
blocks were assessed via the likelihood ratio test (G −
2Log likelihood = 223.57, P < 0.05).
Results
A total of 481 newly confirmed TB cases, including 156
(32.4 %) smear-positive cases and 325 (67.6 %) smear-
negative cases, were enrolled and followed in the cohort,
and no drug resistant case or TB/HIV co-infection were
detected during the study period. 326 (67.8 %) of en-
rolled patients were male, and the age ranged from 14 to
89 years with median age being 39 years. 422 (87.7 %)
patients were long-term residents, and 387 (80.5 %) were
covered by at least one type of health insurance scheme.
The average annual income of participants was 12 758
RMB and only 78 (16.2 %) patients had an income of
over 18 000 RMB (Table 2).
During the study period, 308 participants (64.0 %)
took medications regularly as prescribed and com-
pleted re-examinations as scheduled. Among adherent
patients, the treatment success rate reached 82.5 %
(including 51 smear-positive cases that became nega-
tive and 203 treatment completion cases). Of 173
non-adherence patient, 136 were lost to follow-up, in-
cluding 110 cases that lost contact and 26 that left
for work, totally accounted for 28.2 % of all participants.
The monthly loss to follow-up rates increased each month
with a peak (11.6 %) in the fourth month of treatment
(Fig 1). In addition, the rest 37 non-adherent cases (7.7 %)
took drugs intermittently. No TB case died during the
study period.
280 cases (58.2 %) received TB related education
before or during their chemotherapy, and only 67
(13.9 %) patients said that they were observed when tak-
ing their medication, including twelve (2.4 %) observed
by primary health workers and 55 (11.5 %) by family
members. The rest 414 patients (86.1 %) took drugs
without another person observing. Most patients (60.5 %)
were inquired about and reminded of drug taking and re-
examination through telephone calls during the treatment
course. Few patients (7.9 %) were visited by health workers
Table 1 Definitions for this study
1. Treatment adherence was defined as regular medication intake
and attending all follow-up medical appointments according to the
guidelines. On the contrary, non-adherence referred to missing at
least one dose of drugs or one follow-up appointment during the
treatment course.
2. Treatment success referred to the completion of the full course of
standard treatment and to the curing (become smear-negative) of
newly registered smear-positive cases. For patients who started
treatment as smear-negative cases, treatment success referred to the
completion of the standard treatment course (including the interrupting
cases).
3. Interrupter was defined as a patient who pauses treatment for more
than three doses or for more than a week but less than eight weeks
(eventually returning for treatment).
4. Defaulter was defined as the interruption of treatment for more than
eight consecutive weeks. The default case usually needs re-treatment.
5. Lost to follow-up meant patients who dropped out the cohort
because of loss of contact or any other reasons.
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Table 2 Univariate analysis of association between influencing factors and treatment adherence (n = 481)
Variables Total n Adherent OR (95 % CI) P value
Yes, n (%) No, n (%)
Gender
Male 326 199 (61.0) 127 (39.0) 1.00
Female 155 109 (70.3) 46 (29.7) 0.66 (0.44-0.99) 0.047f
Age (in years)
≤18 43 23 (53.5) 20 (46.5) 1.00
19–49 297 199 (67.1) 98 (32.9) 0.57 (0.30-1.08) 0.820
≥50 141 86 (61.0) 55 (39.0) 0.74 (0.37-1.46) 0.381
Occupationa
Farmer 86 57 (66.3) 29 (33.7) 1.00
Employed worker 166 105 (63.3) 61 (36.8) 1.14 (0.66-1.97) 0.635
Student 65 40 (61.5) 25 (38.5) 1.31 (0.67-2.56) 0.427
Laid-off or unemployed 85 57 (67.1) 28 (32.9) 0.97 (0.51-1.82) 0.914
Others 79 49 (62.0) 30 (38.0) 1.20 (0.64-2.28) 0.569
Educational level
Primary school or below 120 69 (57.5) 51 (42.5) 1.00
Junior middle school 154 102 (66.2) 52 (33.8) 0.69 (0.42-1.13) 0.139
High school and above 207 137 (66.2) 70 (33.8) 0.69 (0.44-1.10) 0.127
Marital status
Married 360 230 (63.9) 130 (36.1) 1.00
Unmarried 106 67 (57.6) 39 (42.5) 1.03 (0.66-1.61) 0.898
Divorced/loss of spouse 15 11 (73.3) 4 (26.7) 0.64 (0.20-2.06) 0.455
Annual per capita income (RMB)b
≤9000 198 118 (59.6) 80 (40.4) 1.00
9000-18000 193 128 (66.3) 65 (33.7) 0.75 (0.50–1.13) 0.169
≥18000 78 51 (65.4) 27 (34.6) 0.78 (0.45–1.35) 0.374
Study site
CC 101 65 (64.4) 36 (35.6) 1.00
SS 185 128 (69.2) 57 (30.8) 0.79 (0.48–1.31) 0.146
YY 195 115 (59.0) 80 (41.0) 1.26 (0.76–2.07) 0.369
Residence statusc
Local residents 422 275 (65.2) 147 (34.8) 1.00
Migrant workers 59 33 (55.9) 26 (44.1) 1.47 (0.85–2.56) 0.106
Time spending to TB care institution
≤ One hour 284 191 (67.3) 93 (32.8) 1.00
> One hour 197 117 (59.4) 80 (40.6) 1.43(0.98–2.09) 0.060
Health insurance
Yes 387 241 (62.3) 146 (37.7) 1.00
No 94 67 (71.3) 27 (28.7) 0.67 (0.41–1.09) 0.103
Pulmonary TB type
Smear-positive 156 105 (67.3) 51 (32.7) 1.00
Smear-negative 325 203 (62.5) 122 (37.5) 1.24 (0.83–1.85) 0.300
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and 152 cases (31.6 %) reported that they never received
any supervision contact (Table 2).
Univariate logistic analysis indicated that non-adherence
was associated with gender male (OR:0.66, 95 % CI:0.44–
0.99), family member observation or monthly medical
service expenses above 450 RMB (OR:4.20, 95 % CI:2.31–
7.65). Protective factors included health worker obser-
vation (OR:0.67, 95 % CI:0.63–0.72), home visit (OR:0.44,
95 % CI:0.01–0.19) and telephone calls supervision
(OR:0.33, 95 % CI:0.22–0.50) (Table 2). Multivariate
Table 2 Univariate analysis of association between influencing factors and treatment adherence (n = 481) (Continued)
TB-related education by physicians
Yes 280 188 (67.1) 92 (32.9) 1.00
No 201 120 (62.7) 81 (37.3) 1.38 (0.952.01) 0.093
Treatment observation
Self-administrated 414 278 (67.2) 136 (32.9) 1.00
Family members 55 18 (32.7) 37 (67.3) 4.20 (2.31–7.65) <0.001
Primary health workers 12 11 (91.7) 1 (8.3) 0.67 (0.63–0.72) <0.001
Regular supervision contact
No supervision contact 152 67 (44.1) 85 (55.9) 1.00
Home visit 38 36 (94.7) 2 (5.3) 0.44 (0.01–0.19) <0.001
Telephone call 291 205 (70.5) 86 (29.6) 0.33 (0.22–0.50) <0.001
Adverse effectsd
Yes 123 80 (65.0) 43 (35.0) 1.00
No 358 228 (63.7) 130 (36.3) 1.06 (0.69–1.63) 0.787
Monthly treatment coste (CNY)
≤450 246 172 (69.9) 74 (30.1) 1.00
>450 235 136 (57.9) 99 (42.1) 1.69 (1.16–2.46) 0.006
aIn the occupation category, employed workers include factory worker, building worker, food service staff, driver, administrative sector staff and teacher; others
include individual peddler, freelance and retired staff
bAnnual per capita income refers to ‘Chongqing Statistic Yearbook’ [Chongqing statistical yearbook (in Chinese). Chongqing: China Statistics Bureau Press; 2013],
the annual income levels of urban and rural areas were categorized into middle-income (CNY 18000) and low-income (CNY 9000). A total of 12 patients did not fill
in this blank
cLocal residents in our study mean the patients have lived and worked in the study sites for at least 12 months; migrant workers refer to the patients temporarily
living in the study sites and receiving treatment but may move along with floating work at any time
dAdverse effects include nausea or vomiting, hands or feet numbness, dizziness, headaches, insomnia, skin rash, etc
eTreatment cost include direct expenditure on self-paid TB drugs, liver protecting drugs, cough remission drugs, traveling, accommodation and nourishment.
450 RMB is the median cost
fVariables with a P-value less than or close to 0.10 in the univariate analysis were included in the multivariate logistic regression analysis
Fig. 1 Monthly lost to follow-up rates of cohort participants. Monthly lost to follow-up rates were calculated as the number of patients quitting
on which month of the treatment divided by the overall 481 participants
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logistic regression (Table 3) showed that patients who
were observed by family members (OR:5.54, 95 %
CI:2.87–10.69) and with monthly treatment expenses
more than 450 RMB (OR:2.08, 95 % CI:1.35–3.19)
were more likely to be non-adherent, while home visit
supervision (OR:0.06, 95 % CI:0.01–0.28) and tele-
phone calls (OR:0.27, 95 % CI:0.17–0.44) were associ-
ated with better treatment adherence (Table 4).
Discussion
Adherence to TB treatment is crucial for effective TB
control. However, current long-term anti-TB treatment
regimen might cause patient non-adherence [19]. In our
study, only 64.0 % of participants were able to adhere to
the defined regimens and completed the whole treatment
course, which was lower than the reported adherence
rates in Jiangsu Province (87.8 %), and Shandong Province
(84.0 %), and the average level of other mountainous prov-
inces (79.0 %). Furthermore, our study found lower adher-
ence rate compared with previous survey data from new
TB patients in Chongqing Province (74.1 %) [6, 12–14],
however, it was probably close to the real situation of
treatment adherence for newly confirmed TB cases given
the prospective cohort data. Several possible reasons for
the low adherence rate observed in our study are: 1) Defi-
nitions of non-adherence for TB treatment varied across
studies. There is yet no empirical evidence or consensus
to the best definition of non-adherence to TB treatment,
although WHO recommended a definition of non-
adherence based on the quantity and timing of missed
medication or hospital appointments. In our study pa-
tients who missed at least one dose of drug or one follow-
up appointment were deemed as non-adherent, which
was relatively rigorous. Some studies have defined it as pa-
tients who missed 10 % or more of the total prescribed
dose of TB drugs and some defined it as discontinue
medication for 6 days [12, 13]. 2) Officially reported data
on TB treatment adherence might be sometimes over-
estimated or over-reported. 3) Adherence rate might have
indeed declined in recent years. 4) A large number of lost
to follow-up participants, who were sometimes excluded
in retrospective surveys and analyses, were also counted
as non-adherent cases in our study because they were un-
likely to attend medical appointments for medicine collec-
tion or re-examinations. Such a high lost to follow-up rate
(28.2 %) has highlighted the importance of maintaining
long-term follow-up with TB patients. In addition, the
dropping out cases of treatment due to relocation for
working suggested that existing internet-based surveil-
lance systems needs strengthening for cross-regional
supervision and management [20]. Moreover, some com-
pulsory measures, such as wage deduction or working
prohibition of workers who do not regularly take TB
drugs, might be effective in the workplace [21]. Having
said that, association between treatment adherence and
possible influencing factors could also be detected based
on available data regardless of the number and time of
participants quitting the cohort because all the lost to
follow-up cases were viewed as non-adherent in factor
analyses.
Observing patients’ taking medication is crucial in TB
therapy. China’s national TB control guidelines are con-
sistent with WHO’s DOTS strategy, in which the trained
agent, including health worker, community volunteer or
family member, are recommended to directly supervise
patients’ medication intake [18, 19]. An optimistic report
on DOTS coverage stated that all TB patients had been
provided with DOTS in China until 2005 [18]. However,
the National TB Epidemiological Survey revealed that
only 64.2 % of detected TB patients were under the case
management of TB dispensaries/designated hospitals
and less than 75 % of them regularly took medication
[10]. In our study, only those patient observed by health
works and family members (13.9 %) met the DOT re-
quirements. Consistent with our findings, DOT coverage
was found low in rural areas (8.4 %), mountainous areas
(28.8 %) and some eastern coastal provinces (21.0 %)
[13, 14, 22]. All these evidence suggested that DOT were
not well implemented in China and some researchers
have argued that DOT may not be a practical policy
Table 3 Dummy variables coding of variable values for multivariate logistic regression
Indicator Category
Dependent variable TB treatment adherence 0 = adherence; 1 = non-adherence
Independent variable Gender 0 = male; 1 = female
Residence status 0 = migrant workers; 1 = local residents
Time spending to TB care institution 0 = ≤ one hour; 1= > one hour
Health insurance 0 = yes; 1 = no
TB-related education by physicians 0 = yes; 1 = no
Treatment observation 0 = self-administrated; 1 = family members; 2 = primary health workers
Regular supervision contact 0 = no supervision contact; 1 = home visit; 2 = telephone call
Monthly treatment cost 0 = ≤450; 1= >450
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option [12]. In fact, Chinese primary health care pro-
viders, including urban community doctors and rural vil-
lage doctors, were important players in the national TB
control system and were responsible for home visits and
supervising drug taking [23]. However, a number of
patients lived in rural or mountain areas without con-
venient transportation, and require long travel time for
home visits. These factors might create a barrier for
proper supervision by health workers [12, 14]. Moreover,
our previous in-depth interviews revealed that primary
health care staff were paid 100 RMB for the full-course
of direct supervision in some counties of Chongqing,
which was far from enough for such demanding work,
and was even insufficient to cover the doctors’ traveling
expenses [24]. Therefore, higher financial incentives may
help encourage health staff to practice better manage-
ment and supervision of TB patients, at least during the
intensive phase (first 2 months) of TB treatment [25].
Family members were also expected to be a possible
alternative for patient supervision. Prior studies confirmed
their positive effect on treatment adherence [20, 22]. But
our findings, on the contrary, suggested that family
observation was probably a risk factor for poor treat-
ment adherence. In practice, where family observation
was allowed, family members might not be strict or
responsible due to their lack of training by the health
care system. Patients were often merely handed medi-
cines and have their spouse watch them swallow the
pills [26]. In addition, definition of family observation
should be clarified because some patients put ambigu-
ous understanding on the duty of family observation.
Sometimes, family members might just “happened to
be in the room” and occasionally remind patients of
taking drugs without actually regularly observing the
medication intake [12]. Further, family members should
receive TB related training in order to supervise patients.
Feasible external intervention technology like the Short
Message Service or smart phone applications might be
helpful for reminding and guiding both patients and family
members [27, 28].
Given the barriers of treatment supervision by health
workers and family members, regular supervision con-
tact between doctors and TB patients is essential. In our
study, factor analysis suggested that supervision contact
via home visits and phone calls could improve treatment
adherence. Our study indicated that 60.5 % of patients
reported that they had received non-scheduled phone
calls from health staff to remind them of medications
and hospital appointments schedule and to pick up TB
medicine before it runs out, on the other hand, home
visits for drug delivery and health services were rarely
seen. In fact, China’s TB guidelines recommended that
new pulmonary TB patients who were provided with
free anti-TB drugs should be observed by health workers
during the whole treatment course [18]. However, direct
observation by health workers were hardly implemented
because most TB facilities in Chongqing were under-
staffed [24], and telephone calls from health workers be-
came the most commonly adopted method for patient
management. Nevertheless, the time of telephone con-
tact might differ across TB facilities due to lack of stand-
ard. In addition, health workers had little incentive for
contacting patients, thus, they may be less motivated to
perform regular supervision calls, which would increase
their workload. Therefore, more specific and stronger
policies are needed to improve and standardize phone
call supervision. In addition, patients in the fourth or
fifth month of their treatment course had a high loss to
follow-up rate. It’s unclear whether this is specific to this
study or is a common problem since previous publica-
tions rarely discussed on this issue.. One possible reason
of loss to follow-up later in the treatment was because
patients had symptom relief and perceived further treat-
ment as unnecessary [11]. This suggest, in later part of
the treatment, more routine contact and reminders are
necessary to inform them of the importance of treatment
Table 4 Multivariate logistic regression on association between
selected factors and treatment non-adherence
Variables OR OR 95 % CI P value
Lower Upper
Gender (compared with ‘male’)
Female 0.69 0.44 1.09 0.109
Residence status (compared
with ‘migrant workers’)
Local residents 0.75 0.39 1.42 0.375
Time spending to TB care institution
(compared with ‘≤ One hour’)
> One hour 1.13 0.65 1.94 0.671
Health insurance (compared with ‘no’)
Yes 0.62 0.34 1.13 0.116
TB-related education by physicians
(compared with ‘yes’)
No 1.02 0.60 1.74 0.934
Treatment observation
(compared with ‘self-administrated’)
Family members 5.54 2.87 10.69 <0.001a
Primary health workers 1.18 0.92 15.18 0.899
Regular supervision contact
(compared with ‘no supervision
contact’)
Home visit 0.06 0.01 0.28 <0.001
Telephone call 0.27 0.17 0.44 <0.001
Monthly treatment cost
(compared with ‘≤450’)
>450 2.08 1.35 3.19 <0.001
aResults were statistically significant when the P-value less than 0.05
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compliance and educate patients on the negative conse-
quences of treatment termination including the high pos-
sibility of TB relapse and drug resistance.
High treatment costs remain a serious problem in TB
control [29]. The treatment cost was found to contribute
to non-adherence in our study. China’s national TB
programme (NTP) guidelines requires free provision of
first-line TB treatment for 6 months, two X-ray examina-
tions and all sputum smear examinations [2]. However,
this so-called “free TB service policy” did not cover the
expenses of second-line TB drugs, drugs related to re-
spiratory symptoms, liver protection, or adverse effects. In
addition, patients have costs related to transportation and
accommodation. The perverse incentives in many TB
facilities or hospitals had significantly increased patients’
financial burden as well [12, 13, 30]. Most TB health
workers in Chongqing had low remuneration for provid-
ing medical service, and the TB department was viewed as
less profitable [24], therefore, TB doctors may over-
prescribe drugs and tests. The profit-seeking behavior was
an important cause of financial burden for TB patients
and some prescribed treatments or tests are not necessary
[30, 31]. To tackle this issue, incentives should be refor-
med to motivate TB health providers to provide appro-
priate treatment. Meanwhile, monitoring mechanisms,
regulations and laws should be established to regulate pro-
vider behaviors. In addition, our study showed that the
average annual income of TB patients was 12 758 RMB,
lower than the average of all Chongqing residents (24 565
RMB) and national average (22 968 RMB) [15]. At pre-
sent, each TB outpatient in Chongqing could receive an
annual reimbursement of 1 000 RMB [32], which was not
enough to cover treatment expenses as most patients
spent hundreds to thousands of RMB per month on TB
treatment. More subsidy or reimbursement is needed to
reduce patients’ financial burden.
Gender difference in treatment adherence was de-
tected in univariate analysis, which was consistent with a
previous study [33]. Interviews with male TB patients
(unpublished) revealed that male patients were more
likely to be non-adherent to prescribed regimen because
of their unhealthy lifestyle and overconfidence in their
health status. Although newly diagnosed TB patients
should receive TB-related education by health workers
[18], only 58.2 % of participants were actually educated
by doctors before or during TB treatment in our study,
which highlights the need for better patient education
because poor TB-related knowledge was often associated
with non-adherence [6, 20].
Several methodology issues need to be discussed.
Firstly, the design of the present study is a prospective
cohort study, for which we could collect data of good
quality and make relatively exact estimates on treatment
history and outcomes, possible explanatory factors. The
design also minimizes patients’ recall bias and avoids
over- or under-estimation in official reports or retro-
spective surveys. Secondly, when analyzing influencing
factors, we actually performed grouping according to
outcome variable (adherence or not) as it was impossible
to group based on diverse individual causal factors, and
given that different types of variables were involved,
multivariate logistic regression was used and odds ratios
(ORs) were directly computed. OR is a commonly used
indicator to detect the association between a disease and
exposure factors in epidemiology research; however, it
might sometimes overstate the effect size and is more
difficult to interpret than the relative risk (RR) which in-
dicates a ratio of two rates [34, 35]. The study also has
several limitations. Firstly, non-randomized sampling
method might give rise to selection bias. Secondly, pa-
tients lost to follow-up were counted as non-adherent
cases in our study based on WHO’s definition, since
those patients were likely to skip medical appointments.
Consequently, it was difficult to measure the treatment
success (cure and completion) as well as regular medica-
tion pattern of those lost cases.
Conclusion
Compared to previous retrospective studies on TB adher-
ence, our prospective cohort study revealed relatively high
non-adherence rate among new pulmonary TB patients.
One third of participants experienced non-adherence, and
patients’ lost to follow-up was not uncommon. Poor treat-
ment supervision and heavy financial burden were identi-
fied as the main causes of non-adherence. Policies are
suggested to be developed to regulate and strengthen
the treatment management of TB patients, and feas-
ible technical methods such as electronic/mobile
health interventions might be introduced to ensure
regular medication intake and follow-up visits. More-
over, better financial incentives for health workers are
needed to improve patients supervision, and more fi-
nancing support, such as promote the reimbursement
level of treatment, are desirable to reduce TB patients’ fi-
nancial burden.
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